Evidence map›Paper›PMID 42015457›Full record

ReviewExpert opinion on drug discovery2026

Leveraging machine learning for selective cannabinoid ligand discovery: methods, challenges, and opportunities.

Bailang Liu, Jie Liu, Wenjing Guo, Ann Varghese, Menghang Xia, Ruili Huang, Tucker A Patterson, Huixiao Hong

Abstract readReview
In one paragraph

Review in Expert opinion on drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bailang LiuNational Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA.
Jie LiuNational Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA.
Wenjing GuoNational Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA.
Ann VargheseNational Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA.
Menghang XiaDivision of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Ruili HuangDivision of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Tucker A PattersonNational Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA.
Huixiao HongNational Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA.

Funding

Intramural FDA HHS FD999999
6 · The paper itself

Abstract

introductionSelective modulation of cannabinoid receptors, particularly achieving CB2 selectivity over CB1, represents a promising strategy for developing safer therapeutics with reduced psychotropic effects. This review examines how machine learning (ML) approaches can address persistent challenges in cannabinoid receptors selectivity and accelerate drug discovery. AREAS COVERED: The authors summarize current ML-based methodologies applied to cannabinoid ligand discovery, focusing on strategies for predicting receptor affinity and selectivity. The literature covered was identified through a PubMed search followed by manual screening to retain studies directly relevant to cannabinoid-focused AI-driven ligand discovery. The review discusses feature engineering approaches, including molecular fingerprints, physicochemical descriptors, and SMILES-based representations, as well as classification and regression algorithms for selectivity prediction. The authors evaluate model performance metrics, dataset limitations, and interpretability challenges. Recent advances in deep learning and generative models for de novo molecular design are also highlighted, with emphasis on their potential to expand chemical space and improve selective ligand identification. EXPERT OPINION: ML has significantly advanced the prediction of cannabinoid receptor selectivity, yet progress remains constrained by data quality, endpoint inconsistency, and limited interpretability. Future efforts integrating curated datasets, mechanistically informed modeling, and generative AI frameworks are expected to substantially enhance the discovery of selective cannabinoid therapeutics.

Indexed as

CannabinoidsDrug DiscoveryMachine LearningAnimalsDrug DesignGenerative Artificial IntelligenceHumansLigandsPredictive Learning ModelsReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2Receptors, CannabinoidCannabinoidsLigandsReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2Receptors, CannabinoidCannabinoid receptorsdeep learninggenerative molecular designligand selectivitymachine learningQSAR modeling

Identifiers

PMID42015457
PMCPMC13595865

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.